You are here: Industry Insights > Bristol-Myers

News List

European backing for Merck's Keytruda rubs salt in Bristol-Myers' wounds biospectrumasia
July 31, 2018
Merck’s Keytruda is one step closer to extending its dominance in the all-important previously untreated lung cancer market.
Bristol-Myers surprise: Threatened I-O drug Opdivo stands its ground in lung cancer fiercepharma
July 30, 2018
Investors may be worried about Bristol-Myers Squibb’s future in lung cancer, but in the meantime, the company’s portfolio is firing on all cylinders.
Bristol-Myers Squibb, Gritstone Oncology Announce Collaboration americanpharmaceuticalreview
July 24, 2018
Bristol-Myers Squibb and Gritstone Oncology announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy,
Gritstone, Bristol-Myers Squibb to trial immunotherapy combos in solid tumors fiercebiotech
July 20, 2018
Gritstone Oncology and Bristol-Myers Squibb are partnering to test the former's personalized neoantigen treatment in combination with the latter's Opdivo and Yervoy in patients with advanced solid tumors. They expect to start a phase 1 trial before the en
How different are I-O stars from Merck, Roche and Bristol-Myers? Depends who you ask fiercepharma
June 07, 2018
It’s no secret that most ASCO watchers decided Merck's data on immuno-oncology star Keytruda would cement its position as king of the all-important lung cancer market.
Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it? fiercepharma
June 05, 2018
Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations.
FDA Accepts Bristol-Myers Combo Application biospace
March 28, 2018
The U.S. Food and Drug Administration (FDA) accepted Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) with Yervoy (ipilimumab) for a type of colorectal cancer.
Bristol-Myers Who? Why a Marriage Between Pfizer and Biogen Makes More Sense biospace
November 15, 2017
Investors love to speculate on mergers and acquisitions (M&A), and one of the hottest topics of speculation recently has been whether someone will buy Bristol-Myers Squibb.
Bristol-Myers posts early checkpoint combination data on fast-advancing rival to Incyte’s IDO1 inhib fiercebiotech
November 13, 2017
Bristol-Myers Squibb has posted interim data on its IDO1 inhibitor in combination with Opdivo.
Bristol-Myers and Halozyme to develop subcutaneous immuno-oncology drugs pharmaceufical-technology
September 18, 2017
The Enhanze technology is based on Halozyme’s patented recombinant human hyaluronidase enzyme (rHuPH20) that removes traditional limitations on the volume of biologics that can be delivered subcutaneously.

Previous page 1 2 3 4 5 Next page